RPL-554 Stable Polymorph for Bioavailability Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The pharmaceutical industry faces challenges in maintaining the stability and bio-availability of polymorphic forms of drugs like RPL-554, which can lead to variations in therapeutic and lethal concentrations, necessitating tight regulatory controls and complex manufacturing processes.
Innovation Solution
A stable polymorphic form of RPL-554 is developed, characterized by specific structural parameters and a crystalline solid composition with a high percentage of the thermodynamically stable polymorph, enhancing stability, compressibility, and bio-availability, and facilitating large-scale cGMP production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple polymorphic forms of RPL-554 are present in the formulation, then different bio-availability characteristics are achieved, but the dosage strength required to obtain ideal blood level becomes unpredictable and may lead to fatal overdosages
Solution Approach 1:
The patent changes the physical state parameter of the compound by defining specific polymorphic forms with distinct crystal structures. Form I and Form II are characterized by specific XRPD patterns, melting points, and solubility characteristics. By controlling which polymorphic form is present in the formulation, the patent ensures consistent bio-availability and predictable dosage requirements, eliminating the risk of fatal overdosages associated with unintended polymorphic transitions.
Solution Approach 2:
The patent addresses the issue of polymorphic transitions by identifying and characterizing thermodynamically stable polymorphic forms (Form I and Form II) that resist unwanted phase changes during storage and processing. By selecting formulations based on these stable forms with well-defined transition temperatures and solubility characteristics, the patent prevents unpredictable bio-availability changes and ensures dosage consistency.
2Object-affected harmful factors
If batch-by-batch monitoring of polymorphic content is implemented to ensure safety, then toxicological risks are reduced, but manufacturing complexity and regulatory burden increase significantly
Solution Approach 1:
The patent performs preliminary characterization of polymorphic forms during the formulation development stage, establishing well-defined XRPD patterns, melting points, and solubility characteristics for Form I and Form II. This advance work creates a knowledge base that simplifies subsequent batch monitoring, as manufacturers can quickly identify the intended polymorphic form using these pre-established criteria without complex real-time analysis systems.
Solution Approach 2:
The patent creates reference standards and fingerprint profiles for each polymorphic form (specific XRPD patterns, DSC thermograms, solubility curves) that can be used as comparison templates. These reference copies enable rapid quality control through simple pattern matching techniques, reducing the need for complex monitoring systems while maintaining high levels of polymorphic content verification.
3Duration of action of stationary object
If the thermodynamically stable polymorph is selected for marketing to ensure long-term stability, then storage stability and shelf life are improved, but dissolution rates and bio-availability may be reduced compared to less stable forms
Solution Approach 1:
The patent identifies and characterizes multiple polymorphic forms with different physical parameters, including Form I and Form II with distinct melting points, solubility characteristics, and dissolution rates. By selecting the appropriate polymorphic form based on the desired balance between stability and bio-availability, the patent optimizes formulation performance for specific therapeutic applications.
Solution Approach 2:
The patent employs composite formulation strategies by combining the selected polymorphic form with excipients, surfactants, or co-solvents that enhance dissolution rates and bio-availability. This approach allows the use of thermodynamically stable polymorphic forms while overcoming their inherently slower dissolution characteristics through formulation design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The stable polymorphic form of RPL-554 provides consistent and reproducible pharmaceutical products with extended shelf life, improved manufacturing processes, and enhanced bio-availability, addressing the issues of variability and regulatory compliance.
Implementation Method 1
A stable polymorphic form of RPL-554 is developed, characterized by specific structural parameters and a crystalline solid composition with a high percentage of the thermodynamically stable polymorph
Data Source
AI summary
The current invention is directed towards a polymorph of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, in the form of a crystalline solid consisting of greater than 99% by weight of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, at least 95% in the polymorphic form of a thermodynamically stable polymorph (I) of N-{2-[(2E)-2-(mesitylimino)-9,10-dimethoxy-4-oxo-6,7-dihydro-2H-pyrimido[6,1-a]-isoquinolin-3(4H)-yl]ethyl}urea, wherein said polymorph is determined by single crystal X-ray structural analysis and X-ray powder diffraction pattern.